Investment Banking and Brokerage

TE HEALTHCARE

TE HEALTHCARE released FY2025 9 Months Earnings on March 16, 2026 (BJT) with actual revenue of HKD 77.51 M and EPS of HKD -0.0022

TE Healthcare released FY2025 Q3 earnings on March 16 (BJT), actual revenue HKD 32.32 M, actual EPS HKD -0.0012

TE HEALTHCARE released FY2025 Q4 earnings on March 16 During-Market (BJT), actual revenue HKD 32.32 M, actual EPS HKD -0.0012

TE Healthcare released FY2025 earnings during market hours on March 16 (BJT), with actual revenue of HKD 109.83 M and EPS of HKD -0.0034

TE Healthcare to Release FY2025 Earnings Report on March 16 During-Market BJT

TE Healthcare released FY2025 Q1 earnings on August 11, 2025 (BJT) with actual revenue HKD 0 and actual EPS HKD 0

TE HEALTHCARE released FY2025 Q2 earnings on August 11 During-Market (BJT), actual revenue HKD 22.59 M, actual EPS HKD -0.0005

TE HEALTHCARE released FY2025 Semi-Annual earnings on August 11 During-Market (BJT), actual revenue HKD 45.18 M, actual EPS HKD -0.001

TE HEALTHCARE to Release FY2025 Semi-Annual Earnings on August 11, 2025 (BJT)

CLSA PREMIUM released FY2024 Q3 earnings on March 17 (BJT), with actual revenue of 20.14 M HKD and EPS of 0.0012 HKD

CLSA PREMIUM released FY2024 9 Months Earnings on March 17 (BJT), actual revenue 75.64 M HKD, actual EPS 0.0043 HKD

CLSA PREMIUM released FY2024 Annual Earnings on March 17 After-Market (BJT), actual revenue 95.77 M HKD, actual EPS 0.0055 HKD

CLSA PREMIUM released FY2024 Q4 earnings on March 17 After-Market (BJT), actual revenue 20.14 M HKD, actual EPS 0.0012 HKD

CLSA PREMIUM FY2024 Annual Earnings Release on March 17, 2025 After-Market BJT

CLSA PREMIUM released FY2023 Q4 earnings on March 11 (BJT), actual revenue 28.52 M HKD, actual EPS 0.001 HKD

CLSA PREMIUM released FY2023 9 Months Earnings on March 11 (BJT), actual revenue 170.42 M HKD, actual EPS 0.0037 HKD

CLSA PREMIUM released FY2023 Q3 earnings on March 11 (BJT), with actual revenue of 28.52 M HKD and EPS of 0.001 HKD

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

06877

513120

510660

589720

159938

159929

Top Eminent Healthcare Group received unanimous shareholder approval for all resolutions at its AGM on May 8, 2026, with 1.5 billion votes cast and no opposition. Shareholders endorsed the 2025 audited financial statements, re-elected four directors, and authorized the board to manage remuneration and share issuance. This reflects strong support for the company's governance and strategy, enhancing its capital management flexibility. Top Eminent Healthcare is a Cayman Islands-incorporated company listed in Hong Kong, focusing on healthcare-related businesses.

Tip Ranks

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

GF CSI All Share Health Care ETF

China Universal 800 Health Care ETF

Top Eminent Healthcare Wins Unanimous Shareholder Backing at AGM

LEGR

512010

Form Health, a prominent provider of science-driven obesity and cardiometabolic care, has been recognized as one of the World’s Most Innovative Companies of 2026 by Fast Company. This prestigious list acknowledges businesses that are revolutionizing their respective industries and impacting culture with their innovative approaches. Among the World’s 50 Most Innovative Companies, Fast Company also acknowledges 720 honorees spanning across 59 sectors and regions. The healthcare category, including Form Health, is notably featured on this list.

Unusual Whales

Geratherm Medical AG

First Trust Indxx Innov

E Fund CSI 300 Health Care ETF

Form Health Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

Tong Ren Tang Healthcare has launched its IPO, aiming to raise up to HK$897.7 million by selling 108 million shares priced between HK$7.30 and HK$8.30 each. The company plans to expand its healthcare network by acquiring and building 10 medical institutions by 2029, capitalizing on the growing demand for traditional Chinese medicine (TCM) services due to China's aging population. With a history of over 350 years, Tong Ren Tang is enhancing its capabilities through AI and digital tools, while also expanding its network through strategic acquisitions. The stock is set to debut on March 30.

benzinga_article

Tong Ren Tang Launches IPO

TPG is exploring options for Asia OneHealthcare, including a potential sale or IPO, as private equity deal activity rises. The Kuala Lumpur-based medical services provider could be valued at up to RM30 billion (S$9.7 billion). TPG is consulting advisers linked to a separate IPO by Sunway Healthcare Holdings Bhd. No final decisions have been made, and TPG may retain its stake. TPG previously acquired hospitals from Asia OneHealthcare for about US$1.2 billion in 2019 and has been active in other Southeast Asian deals.

Businesstimes News

Pro Gbl Listed Pvt

TPG considers sale or IPO of Malaysia-based Asia OneHealthcare: sources

TE HEALTHCARE surged 24.06%; China International Capital Corporation fell 4.74%, with a transaction volume of HKD 160 million; Guotai Junan International fell 5.71%, with a transaction volume of HKD 155 million; China Galaxy fell 4.14%, with a transaction volume of HKD 92.86 million; CITIC Securities fell 3.28%, with a market value of HKD 402.2 billion

HK Stock Alerts

Hong Kong Stock Movement: TE HEALTHCARE acquires Top Eminent II, stock price surges 24.06%! New opportunities in digital healthcare spark market enthusiasm

Top Eminent Healthcare Group Limited will acquire 100% of Top Eminent II Limited for HK$100.3 million, a connected transaction under Hong Kong listing rules. The acquisition allows Top Eminent to consolidate financial results from PRC entities in internet-based healthcare. As the vendor is a subsidiary of the controlling shareholder, independent shareholder approval is required. An Independent Board Committee has been formed, and Ignite Capital (Asia Pacific) Limited will serve as the independent financial adviser. The latest analyst rating for CLSA Premium Ltd. (HK:6877) is a Hold with a price target of HK$0.15.

Top Eminent Healthcare to Acquire Online Healthcare Platform in HK$100.3 Million Connected Deal

TE HEALTHCARE issued a profit warning, expecting to record a consolidated loss attributable to shareholders of approximately HKD 7.1 million for the year ending December 31, 2025, while recording a consolidated profit attributable to shareholders of approximately HKD 11.3 million for the fiscal year 2024. The group pointed out that profitability is affected by high administrative and operating expenses arising from the expansion of B2C sales channels and digital marketing activities, as well as increased professional and legal fees due to specific corporate transactions and litigation. Other income is expected to decrease by 71% to approximately HKD 4.6 million, mainly due to a decline in foreign exchange gains and interest-related income

AASTOCKS

"Profit Warning" TE HEALTHCARE expects to turn from profit to loss for the full year, with a loss of approximately HKD 7.1 million

Top Eminent Healthcare Group Limited announced the resignation of independent non-executive director Mr. Zhou Zuyu, effective December 31, 2025, due to other commitments. Mr. Zhou Jiannan will replace him as INED, lead INED, and chairman of the remuneration committee starting January 1, 2026, with an annual fee of HK$240,000. His extensive experience in financial markets will enhance the company's governance. The current analyst rating for CLSA Premium Ltd. (HK:6877) is a Hold, with a price target of HK$0.15.

Top Eminent Healthcare Refreshes Independent Board Leadership With Appointment of Veteran Market Executive

TE HEALTHCARE(06877.HK)